Should get close to $4bn if they succeed in registering FDA approved Nasal Spray delivery for mulitple indications...however, in my opinion, i believe LTP will be acquired shortly after FDA by Big Pharma to prevent any significant disruption of current market suppliers in ED.
Should LTP not get acquired and realise USD$600m revenue (Spontan only) with 50% EBITDA, only using a multiplier of 10, then USD$3Bn is definitely achievable..
The above snippet IMO is a good sign, doesnt appear as funds required for operations, , only a guess but funds may be required for a new nasal spray indication or fast tracking FDA...time will tell.
Fast-tracking an FDA submission involves: Application fees: Up to $3.57 million (for drugs/biologics). Development/clinical trials: $10 million–$2 billion. Consulting and preparation: $50,000–$1 million.
LTP Price at posting:
$1.05 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)